KPV: Alpha-MSH Fragment for Inflammation Research

KPV (Lys-Pro-Val) is a naturally occurring tripeptide representing the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). Despite lacking the melanocortin receptor binding domain, KPV retains potent anti-inflammatory activity through receptor-independent mechanisms, making it a valuable tool for inflammation and immune research.

Origin from Alpha-MSH

Alpha-MSH is a 13-amino acid peptide hormone with both pigmentary and anti-inflammatory functions. The full sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val. The KPV sequence (positions 11-13) represents the minimal active fragment for anti-inflammatory activity.

Interestingly, KPV lacks the His-Phe-Arg-Trp core sequence required for melanocortin receptor binding, yet it retains robust anti-inflammatory effects. This suggests an alternative mechanism of action independent of classical MC1R signaling.

Mechanisms of Action

NF-κB Inhibition

Research demonstrates that KPV potently inhibits NF-κB activation. The peptide blocks the nuclear translocation of NF-κB subunits, preventing transcription of pro-inflammatory genes. This results in reduced production of cytokines including TNF-α, IL-1β, IL-6, and IL-8.

Direct Antimicrobial Activity

KPV exhibits direct antimicrobial properties against various bacterial strains through membrane disruption. This dual anti-inflammatory and antimicrobial activity may be particularly relevant in infection-associated inflammation research.

Research Applications

• Inflammatory bowel disease models (colitis research)
• Skin inflammation and wound healing studies
• Arthritis and joint inflammation research
• Neuroinflammation investigations
• Oral mucositis and gastrointestinal inflammation models

Gastrointestinal Research

KPV has shown particular promise in GI inflammation research. Studies in colitis models demonstrate reduced mucosal inflammation, improved epithelial barrier function, and accelerated tissue repair. The peptide's stability in the gastrointestinal environment makes it suitable for oral administration studies.

Combination with Other Peptides

KPV is often studied alongside BPC-157 due to their complementary mechanisms in gut research. While both reduce inflammation, they operate through distinct pathways - KPV through NF-κB inhibition and BPC-157 through growth factor and nitric oxide modulation.